Standard Care for Socioeconomic Status

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
TSET Health Promotion Research Center, Oklahoma City, OK
Socioeconomic Status+6 More
Standard Care - Other
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

Although many women initially quit smoking during pregnancy, most will return to smoking by the end of pregnancy or during the first 6 months postpartum.The findings of a meta-analysis have concluded that incentivizing smoking cessation is an effective approach among pregnant women. The proposed pilot project is designed to evaluate the feasibility and potential efficacy of offering small financial incentives for the completion of smoking cessation coaching among pregnant women with Medicaid insurance who contact the Oklahoma Tobacco Helpline (OTH). The study will enroll 100 pregnant women who will be randomly assigned to OTH care or OTH plus escalating incentives (OTH+I) for completing up to 5 coaching calls over the first 8 weeks after enrolling (prepartum) In addition, participants will be incentivized for completing up to 2 postpartum coaching calls by 8 weeks postpartum. Feasibility outcomes for the incentives-based intervention will focus on coaching call completion, rates of prepartum and postpartum follow-up, and perceptions of the intervention. Potential effectiveness will be evaluated by comparing self-reported smoking abstinence rates in OTH+I relative to OTH alone at 12 weeks post-enrollment (prepartum) and 12 weeks postpartum.

Eligible Conditions

  • Socioeconomic Status
  • Contingency Management
  • Tobacco Use
  • Tobacco
  • Cessation, Tobacco
  • Pregnant State
  • Smoking Cessation Financial Incentives

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 12 weeks postpartum

12 weeks post enrollment
Biochemically verified abstinence 12 weeks post enrollment
Self-reported abstinence 12 weeks post enrollment
12 weeks postpartum
Biochemically verified abstinence 12 weeks postpartum
Self-reported abstinence 12 weeks postpartum

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard Care
1 of 2
Standard Care + Financial Incentives
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Standard Care · No Placebo Group · N/A

Standard Care + Financial IncentivesExperimental Group · 2 Interventions: Standard Care, Standard Care + Financial Incentives · Intervention Types: Other, Behavioral
Standard Care
Other
ActiveComparator Group · 1 Intervention: Standard Care · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard Care + Financial Incentives
2017
N/A
~320

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks postpartum
Closest Location: TSET Health Promotion Research Center · Oklahoma City, OK
Photo of oklahoma city 1Photo of oklahoma city 2Photo of oklahoma city 3
2022First Recorded Clinical Trial
2 TrialsResearching Socioeconomic Status
3 CompletedClinical Trials

Who is running the clinical trial?

University of OklahomaLead Sponsor
410 Previous Clinical Trials
95,506 Total Patients Enrolled
1 Trials studying Socioeconomic Status
160 Patients Enrolled for Socioeconomic Status

Eligibility Criteria

Age 18+ · Female Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 35 years.
You are able to provide a copy/photo of your ID/driver's license or other documentation of identity.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.